BioNeutral Group Establishes Advisory Board for Euro-Asian Markets and Appoints Chairman

BioNeutral Group, Inc. (OTCBB:BONU), a specialty chemical technology-based life science company, reports that it has decided to accelerate commercial activities for its Ygiene™ hospital disinfectants first within the European Union being followed closely by the Asian markets. To assist in this effort, BioNeutral has established an Advisory Board for Euro-Asian markets.

 

Sir Anthony Jolliffe, GBE, DL, DSc, the former Lord Mayor of London, will serve as Chairman of the Advisory Board. A global entrepreneur and businessman, Sir Anthony currently holds and has held numerous directorships of private and listed companies in the U.S. and Japan. He is a director of Turbochef Technologies Inc., Chairman of Medicsight International Ltd., International Advisor to Xioyia Group China, and Chairman of Golden Tulip Hotels. He is currently involved in major business projects in China, Europe, the Middle East, the U.S. and the U.K. as a shareholder, partner, advisor and consultant, and has led international trade missions to Spain, Japan, Germany, and other countries.

 

Dr. Andy Kielbania, Chief Scientist for BioNeutral, stated: “We are extremely pleased that Sir Anthony has agreed to Chair our newly formed Advisory Board for Euro-Asian markets.”

 

Stephen J. Browand, President and CEO of BioNeutral, stated: “As BioNeutral steps up its efforts to make its products available in Euro-Asian markets, we could ask for no better advisor than Sir Anthony. He has proven himself supremely talented in facilitating the commercial opportunities within both the European and Asian markets that are open to U.S.-based companies such as ours. I have no doubt that his leadership and activities as Chairman will result in an increased level of interest abroad for BioNeutral’s line of products, and ultimately result in a revenue stream as these markets are opened up to us. We expect to be adding more members to the Board in the near future to assist us as we forge plans to penetrate this strategically and economically important region.”

 

Headquartered at the New Jersey Institute of Technology/EDC in Newark, New Jersey, BioNeutral Group, Inc., is a specialty chemical technology-based life science company that is developing and intends to commercialize a combinational chemistry-based technology which can neutralize harmful environmental contaminants, toxins and dangerous microorganisms including bacteria, viruses, mold, fungi and spores. The formulations, including Ygiene™ and Ogiene™, are both eco-friendly. The Company has combined these widely used compounds in highly specialized ways to create products that dramatically enhance disinfecting and cleaning results; products include BioNeutralizers and ChemoNeutralizers. BioNeutral’s proprietary platform technology has been proven effective in surface, water and airborne applications. Its antimicrobial line of products under the Ygiene™ brand have not yet been submitted to the EPA for approval for sale in the United States; however they have been approved in Germany and are allowed in the UK, France and Sweden.

 

BioNeutral routinely tests its formulations against those of its competitors. The results are published to let shareholders know how the Company's technology compares with known formulations in the market place. Any product claim for antimicrobial activity requires approval from the EPA or FDA, depending upon where and how the formulations are used. The EPA and FDA have not reviewed or confirmed the Company's data and findings. BioNeutral's antimicrobial formulations will be marketed under the brand name Ygiene™ and are not yet available for sale in the United States.

Source: Business Wire/Yahoo Finance